Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

Hikma Pharmaceuticals Plc (HKMPF) had Revenue of $3.13B for the most recently reported fiscal year, ending 2024-12-31.

Quarterly Annual

Figures for fiscal year ending 2024-12-31

Income Statement Financials
Revenue	$3.13B
Net Income	$359.00M
Cost of Goods Sold	$1.71B
Gross Profit	$1.42B
Operating Expenses	$2.52B
Operating Income	$612.00M
Non-Operating Income/Expense	$-157.00M
Pre-Tax Income	$455.00M
Normalized Pre-Tax Income	$453.00M
Income after Taxes	$362.00M
Income from Continuous Operations	$362.00M
Consolidated Net Income/Loss	$362.00M
Normalized Income after Taxes	$359.59M
EBIT	$612.00M
EBITDA	$612.00M
Weighted-Average Shares Outstanding (Basic)	221.33M
Weighted-Average Shares Outstanding (Diluted)	223.49M
Earnings per Share (EPS) (Basic)	$1.62
Earnings per Share (EPS) (Diluted)	$1.61
Balance Sheet Financials
Current Assets	$2.26B
Property, Plant, and Equipment	$1.28B
Long-Term Assets	$2.87B
Total Assets	$5.13B
Current Liabilities	$1.98B
Long-Term Debt	$653.00M
Long-Term Liabilities	$834.00M
Total Liabilities	$2.81B
Common Equity	$2.32B
Tangible Shareholders Equity	$1.17B
Shareholders Equity	$2.32B
Common Shares Outstanding	221.89M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$564.00M
Cash Flow from Investing Activities	$-381.00M
Cash Flow from Financial Activities	$-188.00M
Beginning Cash	$205.00M
End Cash	$188.00M
Increase/Decrease in Cash	$-17.00M
Stock-Based Compensation	$27.00M
Common Stock Dividends Paid	$-178.00M
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	1.14
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.22
Debt to Equity Ratio	0.56
Gross Margin	45.25%
Operating Margin	19.57%
EBIT Margin	19.57%
EBITDA Margin	19.57%
Pre-Tax Profit Margin	14.55%
Profit Margin	11.48%
Free Cash Flow	$399.00M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.61
Inventory Turnover	1.74
Receiveable Turnover	3.29
Days Sales in Receivables	110.77
Return on Equity	15.60%
Return on Tangible Equity	31.07%
Return on Assets	7.05%
Return on Investments	12.17%
Book Value Per Share	$10.46
Free Cash Flow per Share	$1.79
Operating Cash Flow per Share	$2.52

Data from Zacks Investment Research, Inc.